Adaptive Biotechnologies Q4 Results Exceed Expectations, Analysts Boost 2026 Revenue Forecasts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) reported better-than-expected full-year results, with revenues of $277m leading estimates by 4.1% and statutory losses of $0.39 per share smaller than expected. Analysts have updated their earnings model, forecasting 2026 revenues of $277.2m and losses of $0.49 per share, up from previous estimates. The consensus price target remains at $20.86, with a relatively close grouping of estimates.